Company Interview / The smallcap fighting bedbugs & mosquitoes

Key points:

Bio-Gene Technology receives $3m in grants for insect control innovation.Development of wearable mosquito repellents and bedbug solutions in progress.Shift towards natural compounds presents growth in multiple industry sectors.

Tim Grogan of Bio-Gene Technology (ASX: BGT) shares exciting news about securing $3m in grants from the US Department of Defense for developing innovative insect control solutions using natural compounds.

Tim highlights plans to develop a wearable device for defence personnel against mosquitoes, targeting vector-borne diseases like dengue and malaria. There's also a focus on addressing bedbug infestations, which are problematic in places like Paris.

Additionally, the move away from synthetic chemistry to natural compounds is noted, with Bio-Gene poised for significant growth in public health, agriculture, and consumer sectors. The market's positive reaction underscores the potential impact of these innovations.